Jump to content

European Lead Factory: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Filled in 4 bare reference(s) with reFill (); Copyedit (minor); formatted references
Line 1: Line 1:
{{Orphan|date=June 2017}}
{{Orphan|date=June 2017}}


The ''' European Lead Factory''' is a [[Public–private partnership|public-private partnership]] that aims to accelerate early [[drug discovery]] in Europe.<ref>https://www.imi.europa.eu/content/european-lead-factory</ref> The European Lead Factory is funded by the [[Innovative Medicines Initiative]] and consists of a pan-European consortium that includes 7 [[European Federation of Pharmaceutical Industries and Associations|pharmaceutical companies]] as well as partners from academia and [[small and medium-sized enterprises]] (SMEs).<ref>{{Cite web|url=http://www.euronews.com/2016/12/28/business-planet-innovative-medicines-initiative-imi|title=The vital role of SMEs in medical research|date=2016-12-28|website=euronews|access-date=2017-05-17}}</ref><ref>https://www.europeanleadfactory.eu/about/partners/</ref>
The ''' European Lead Factory''' is a [[Public–private partnership|public-private partnership]] that aims to accelerate early [[drug discovery]] in Europe.<ref>{{cite web|url=https://www.imi.europa.eu/content/european-lead-factory|title=IMI Innovative Medicines Initiative - ELF - European Lead Factory|website=IMI Innovative Medicines Initiative}}</ref> The European Lead Factory is funded by the [[Innovative Medicines Initiative]] and consists of a pan-European consortium that includes 7 [[European Federation of Pharmaceutical Industries and Associations|pharmaceutical companies]] as well as partners from academia and [[small and medium-sized enterprises]] (SMEs).<ref>{{Cite web|url=http://www.euronews.com/2016/12/28/business-planet-innovative-medicines-initiative-imi|title=The vital role of SMEs in medical research|date=2016-12-28|website=euronews|access-date=2017-05-17}}</ref><ref>{{cite web|url=https://www.europeanleadfactory.eu/about/partners/|title=Partners - European Lead Factory|website=www.europeanleadfactory.eu}}</ref>


== Drug Discovery Platform ==
== Drug discovery platform ==
The European Lead Factory is operational since 2013 and consists of two main components: the Joint European [[Chemical library|Compound Library]]<ref>https://www.europeanleadfactory.eu/about/assets/joint-european-compound-library/</ref> and the European Screening Centre.<ref>https://www.europeanleadfactory.eu/about/assets/eu-screening-centre/</ref> Together these elements provide a platform for pharmaceutical researchers in Europe to identify drug discovery starting points, by connecting innovative drug targets to high-quality [[small molecule]]s.<ref>The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery. Karawajczyk A. et al., Frontiers in Medicine 2016; 3:75. doi: 10.3389/fmed.2016.00075</ref><ref>The European Lead Factory – An experiment in collaborative drug discovery - Laverty HG, et al., Journal of Medicines Development Sciences 1.1 (2015), doi: 10.18063/JMDS.2015.01.009</ref> The result is defined in a ‘hit list’: a number of compounds that show affinity for the target. The compounds on those lists can either be used as probes to better understand biological pathways or as starting points for lead discovery efforts for novel drugs. These hits can be further optimised outside of the European Lead Factory, for affinity but also for drug-like properties as selectivity, solubility and metabolism in the human body. The ultimate goal is that these candidate drugs will solve unmet medical needs when fully approved as drug by the authorities.
The European Lead Factory is operational since 2013 and consists of two main components: the Joint European [[Chemical library|Compound Library]]<ref>{{cite web|url=https://www.europeanleadfactory.eu/about/assets/joint-european-compound-library/|title=Joint European Compound Library - European Lead Factory|website=www.europeanleadfactory.eu}}</ref> and the European Screening Centre.<ref>{{cite web|url=https://www.europeanleadfactory.eu/about/assets/eu-screening-centre/|title=EU Screening Centre - European Lead Factory|website=www.europeanleadfactory.eu}}</ref> Together these elements provide a platform for pharmaceutical researchers in Europe to identify drug discovery starting points, by connecting innovative drug targets to high-quality [[small molecule]]s.<ref>{{Cite journal|last=Karawajczyk|first=Anna|last2=Orrling|first2=Kristina M.|last3=Vlieger|first3=De|last4=B|first4=Jon S.|last5=Rijnders|first5=Ton|last6=Tzalis|first6=Dimitrios|date=2017|title=The European Lead Factory: A Blueprint for Public–Private Partnerships in Early Drug Discovery|url=http://journal.frontiersin.org/article/10.3389/fmed.2016.00075/full|journal=Frontiers in Medicine|language=English|volume=3|doi=10.3389/fmed.2016.00075|issn=2296-858X|pmc=PMC5243859|pmid=28154815}}</ref><ref>The European Lead Factory – An experiment in collaborative drug discovery - Laverty HG, et al., Journal of Medicines Development Sciences 1.1 (2015), doi: 10.18063/JMDS.2015.01.009</ref> The result is defined in a ‘hit list’: a number of compounds that show affinity for the target. The compounds on those lists can either be used as probes to better understand biological pathways or as starting points for lead discovery efforts for novel drugs. These hits can be further optimised outside of the European Lead Factory, for affinity but also for drug-like properties as selectivity, solubility and metabolism in the human body. The ultimate goal is that these candidate drugs will solve unmet medical needs when fully approved as drug by the authorities.


== Open Innovation ==
== Open innovation ==
The Joint European Compound Library has a collection of around 500,000 chemical compounds selected from private company collections<ref>The Joint European Compound Library: boosting precompetitive research. - Besnard J, Jones PS, Hopkins AL, Pannifer AD, Drug Discov Today. 2015 Feb;20(2):181-6, doi:10.1016/j.drudis.2014.08.014. Epub 2014 Sep 6.</ref> and complemented by the novel molecules synthesised by the European Lead Factory chemistry partners.<ref>Expansion of chemical space for collaborative lead generation and drug discovery – the European Lead Factory Perspective - A. Karawajczyk, F. Giordanetto, J. Benningshof, D. Hamza, T. Kalliokoski, K. Pouwer, R. Morgentin, A. Nelson, G. Müller, A. Piechot, D. Tzalis, Drug Discovery Today 20 (11), 1310–1316, doi: 10.1016/j.drudis.2015.09.009 Epub 2015 Sep 30</ref> European researchers from academia as well as SMEs and patient organisations submit their [[biological target]] to be screened against the compound collection by the European Lead Factory researchers by means of industrial standard [[high-throughput screening]].<ref>The importance of triaging in determining the quality of output from high-throughput screening - Jones PS, McElroy S, Morrison A and Pannifer A., Future Medicinal Chemistry 2015;7(14):1847-52. doi: 10.4155/fmc.15.121 Epub 2015 Sep 30</ref>
The Joint European Compound Library has a collection of around 500,000 chemical compounds selected from private company collections<ref>{{Cite journal|last=Besnard|first=Jérémy|last2=Jones|first2=Philip S.|last3=Hopkins|first3=Andrew L.|last4=Pannifer|first4=Andrew D.|date=2015-02-01|title=The Joint European Compound Library: boosting precompetitive research|url=http://linkinghub.elsevier.com/retrieve/pii/S1359644614003419|journal=Drug Discovery Today|volume=20|issue=2|pages=181–186|doi=10.1016/j.drudis.2014.08.014|issn=1359-6446|access-date=2015-09-06|via=}}</ref> and complemented by the novel molecules synthesised by the European Lead Factory chemistry partners.<ref>{{Cite journal|last=Karawajczyk|first=Anna|last2=Giordanetto|first2=Fabrizio|last3=Benningshof|first3=Jorg|last4=Hamza|first4=Daniel|last5=Kalliokoski|first5=Tuomo|last6=Pouwer|first6=Kees|last7=Morgentin|first7=Remy|last8=Nelson|first8=Adam|last9=Müller|first9=Gerhard|date=2015-11-01|title=Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective|url=http://linkinghub.elsevier.com/retrieve/pii/S1359644615003499|journal=Drug Discovery Today|volume=20|issue=11|pages=1310–1316|doi=10.1016/j.drudis.2015.09.009|issn=1359-6446|access-date=2015-09-30|via=}}</ref> European researchers from academia as well as SMEs and patient organisations submit their [[biological target]] to be screened against the compound collection by the European Lead Factory researchers by means of industrial standard [[high-throughput screening]].<ref>{{Cite journal|last=Jones|first=Philip|last2=McElroy|first2=Stuart|last3=Morrison|first3=Angus|last4=Pannifer|first4=Andrew|date=2015-09-01|title=The importance of triaging in determining the quality of output from high-throughput screening|url=http://www.future-science.com/doi/10.4155/fmc.15.121|journal=Future Medicinal Chemistry|language=EN|volume=7|issue=14|pages=1847–1852|doi=10.4155/fmc.15.121|issn=1756-8919|access-date=2015-09-30|via=}}</ref>


==References==
==References==

Revision as of 18:30, 1 June 2018

The European Lead Factory is a public-private partnership that aims to accelerate early drug discovery in Europe.[1] The European Lead Factory is funded by the Innovative Medicines Initiative and consists of a pan-European consortium that includes 7 pharmaceutical companies as well as partners from academia and small and medium-sized enterprises (SMEs).[2][3]

Drug discovery platform

The European Lead Factory is operational since 2013 and consists of two main components: the Joint European Compound Library[4] and the European Screening Centre.[5] Together these elements provide a platform for pharmaceutical researchers in Europe to identify drug discovery starting points, by connecting innovative drug targets to high-quality small molecules.[6][7] The result is defined in a ‘hit list’: a number of compounds that show affinity for the target. The compounds on those lists can either be used as probes to better understand biological pathways or as starting points for lead discovery efforts for novel drugs. These hits can be further optimised outside of the European Lead Factory, for affinity but also for drug-like properties as selectivity, solubility and metabolism in the human body. The ultimate goal is that these candidate drugs will solve unmet medical needs when fully approved as drug by the authorities.

Open innovation

The Joint European Compound Library has a collection of around 500,000 chemical compounds selected from private company collections[8] and complemented by the novel molecules synthesised by the European Lead Factory chemistry partners.[9] European researchers from academia as well as SMEs and patient organisations submit their biological target to be screened against the compound collection by the European Lead Factory researchers by means of industrial standard high-throughput screening.[10]

References

  1. ^ "IMI Innovative Medicines Initiative - ELF - European Lead Factory". IMI Innovative Medicines Initiative.
  2. ^ "The vital role of SMEs in medical research". euronews. 2016-12-28. Retrieved 2017-05-17.
  3. ^ "Partners - European Lead Factory". www.europeanleadfactory.eu.
  4. ^ "Joint European Compound Library - European Lead Factory". www.europeanleadfactory.eu.
  5. ^ "EU Screening Centre - European Lead Factory". www.europeanleadfactory.eu.
  6. ^ Karawajczyk, Anna; Orrling, Kristina M.; Vlieger, De; B, Jon S.; Rijnders, Ton; Tzalis, Dimitrios (2017). "The European Lead Factory: A Blueprint for Public–Private Partnerships in Early Drug Discovery". Frontiers in Medicine. 3. doi:10.3389/fmed.2016.00075. ISSN 2296-858X. PMC 5243859. PMID 28154815.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  7. ^ The European Lead Factory – An experiment in collaborative drug discovery - Laverty HG, et al., Journal of Medicines Development Sciences 1.1 (2015), doi: 10.18063/JMDS.2015.01.009
  8. ^ Besnard, Jérémy; Jones, Philip S.; Hopkins, Andrew L.; Pannifer, Andrew D. (2015-02-01). "The Joint European Compound Library: boosting precompetitive research". Drug Discovery Today. 20 (2): 181–186. doi:10.1016/j.drudis.2014.08.014. ISSN 1359-6446. Retrieved 2015-09-06.
  9. ^ Karawajczyk, Anna; Giordanetto, Fabrizio; Benningshof, Jorg; Hamza, Daniel; Kalliokoski, Tuomo; Pouwer, Kees; Morgentin, Remy; Nelson, Adam; Müller, Gerhard (2015-11-01). "Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective". Drug Discovery Today. 20 (11): 1310–1316. doi:10.1016/j.drudis.2015.09.009. ISSN 1359-6446. Retrieved 2015-09-30.
  10. ^ Jones, Philip; McElroy, Stuart; Morrison, Angus; Pannifer, Andrew (2015-09-01). "The importance of triaging in determining the quality of output from high-throughput screening". Future Medicinal Chemistry. 7 (14): 1847–1852. doi:10.4155/fmc.15.121. ISSN 1756-8919. Retrieved 2015-09-30.
Retrieved from "https://en.wikipedia.org/w/index.php?title=European_Lead_Factory&oldid=843973712"